Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rosette-forming glioneuronal tumour: an uncommon posterior fossa tumour.
Ökçesiz İ, Dönmez H, Sarı ZE, Deniz K, Şahin A. Ökçesiz İ, et al. Among authors: deniz k. Br J Hosp Med (Lond). 2024 Jan 2;85(1):1. doi: 10.12968/hmed.2022.0464. Epub 2024 Jan 5. Br J Hosp Med (Lond). 2024. PMID: 38300686 Free article. No abstract available.
Alantolactone ameliorates graft versus host disease in mice.
Odabas GP, Aslan K, Suna PA, Kendirli PK, Erdem Ş, Çakır M, Özcan A, Yılmaz E, Karakukcu M, Donmez-Altuntas H, Yay AH, Deniz K, Altay D, Arslan D, Canatan H, Eken A, Unal E. Odabas GP, et al. Among authors: deniz k. Int Immunopharmacol. 2024 Feb 15;128:111560. doi: 10.1016/j.intimp.2024.111560. Epub 2024 Jan 20. Int Immunopharmacol. 2024. PMID: 38246003
Treatment with tumor-treating fields (TTFields) suppresses intercellular tunneling nanotube formation in vitro and upregulates immuno-oncologic biomarkers in vivo in malignant mesothelioma.
Sarkari A, Korenfeld S, Deniz K, Ladner K, Wong P, Padmanabhan S, Vogel RI, Sherer LA, Courtemanche N, Steer C, Wainer-Katsir K, Lou E. Sarkari A, et al. Among authors: deniz k. Elife. 2023 Nov 13;12:e85383. doi: 10.7554/eLife.85383. Elife. 2023. PMID: 37955637 Free PMC article.
Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Keklik M, Deveci B, Celik S, Deniz K, Gonen ZB, Zararsiz G, Saba R, Akyol G, Ozkul Y, Kaynar L, Keklik E, Unal A, Cetin M, Jones OY. Keklik M, et al. Among authors: deniz k. Ann Hematol. 2023 Jun;102(6):1537-1547. doi: 10.1007/s00277-023-05216-3. Epub 2023 Apr 17. Ann Hematol. 2023. PMID: 37067556
159 results